Minimal Residual Disease Market Players:
- Roche Diagnostics Corporation
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott Laboratories
- Siemens Healthineers
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- Becton, Dickinson and Company
- Thermo Fisher Scientific Inc.
- Qiagen N.V.
- Adaptive Biotechnologies Corporation
- Invivoscribe, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of minimal residual disease is assessed at USD 2.47 billion.
The global minimal residual disease market size was valued at over USD 2.21 billion in 2025 and is expected to expand at a CAGR of more than 13.3%, surpassing USD 7.7 billion revenue by 2035.
North America minimal residual disease market will secure over 42% share, driven by rising cancer cases and increasing adoption of minimal residual disease techniques, forecast period 2026–2035.
Key players in the market include Roche Diagnostics Corporation, Abbott Laboratories, Siemens Healthineers, Bio-Rad Laboratories, Inc., Illumina, Inc., Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Qiagen N.V., Adaptive Biotechnologies Corporation, Invivoscribe, Inc.
